JP2020100630A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020100630A5 JP2020100630A5 JP2020019337A JP2020019337A JP2020100630A5 JP 2020100630 A5 JP2020100630 A5 JP 2020100630A5 JP 2020019337 A JP2020019337 A JP 2020019337A JP 2020019337 A JP2020019337 A JP 2020019337A JP 2020100630 A5 JP2020100630 A5 JP 2020100630A5
- Authority
- JP
- Japan
- Prior art keywords
- ofatumumab
- multiple sclerosis
- during
- administered
- regimen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960002450 ofatumumab Drugs 0.000 claims description 47
- 238000012423 maintenance Methods 0.000 claims description 17
- 201000006417 multiple sclerosis Diseases 0.000 claims description 15
- 208000007118 chronic progressive multiple sclerosis Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 5
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 229940090047 auto-injector Drugs 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 1
- 229920000053 polysorbate 80 Polymers 0.000 claims 1
- 229940068968 polysorbate 80 Drugs 0.000 claims 1
- 235000017281 sodium acetate Nutrition 0.000 claims 1
- 239000001632 sodium acetate Substances 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 18
- 230000003902 lesion Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662374986P | 2016-08-15 | 2016-08-15 | |
| US62/374,986 | 2016-08-15 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Division JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020100630A JP2020100630A (ja) | 2020-07-02 |
| JP2020100630A5 true JP2020100630A5 (enExample) | 2020-09-24 |
| JP7198786B2 JP7198786B2 (ja) | 2023-01-04 |
Family
ID=59901554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Active JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
| JP2020019337A Active JP7198786B2 (ja) | 2016-08-15 | 2020-02-07 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018550539A Active JP6851391B2 (ja) | 2016-08-15 | 2017-08-11 | オファツムマブを用いた多発性硬化症の治療レジメンおよび治療方法 |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US11161909B2 (enExample) |
| EP (4) | EP4371611A3 (enExample) |
| JP (2) | JP6851391B2 (enExample) |
| KR (2) | KR20200136503A (enExample) |
| CN (5) | CN109641965A (enExample) |
| AU (2) | AU2017311664C1 (enExample) |
| CA (2) | CA3030530C (enExample) |
| CY (1) | CY1123350T1 (enExample) |
| DE (1) | DE202017007542U1 (enExample) |
| DK (2) | DK3497132T3 (enExample) |
| ES (2) | ES2954259T3 (enExample) |
| FI (1) | FI3733712T3 (enExample) |
| HR (2) | HRP20201388T1 (enExample) |
| HU (2) | HUE063625T2 (enExample) |
| IL (4) | IL276890B2 (enExample) |
| LT (2) | LT3733712T (enExample) |
| MX (1) | MX388593B (enExample) |
| PL (2) | PL3497132T3 (enExample) |
| PT (2) | PT3733712T (enExample) |
| RS (2) | RS60807B1 (enExample) |
| RU (1) | RU2749951C2 (enExample) |
| SI (2) | SI3733712T1 (enExample) |
| TW (1) | TWI752995B (enExample) |
| WO (1) | WO2018033841A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109641965A (zh) * | 2016-08-15 | 2019-04-16 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| CN118403156A (zh) | 2019-09-11 | 2024-07-30 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| US20220389109A1 (en) * | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| IL296701A (en) * | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum |
| WO2022219057A1 (en) * | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4816401A (en) | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
| WO1987002671A1 (en) | 1985-11-01 | 1987-05-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| AU5108201A (en) | 2000-03-30 | 2001-10-15 | Amgen Inc | Cd20/ige-receptor like molecules and uses thereof |
| CA2634294A1 (en) | 2000-08-03 | 2002-02-14 | Therapeutic Human Polyclonals, Inc. | Production of humanized antibodies in transgenic animals |
| WO2004035607A2 (en) | 2002-10-17 | 2004-04-29 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US8084582B2 (en) | 2003-03-03 | 2011-12-27 | Xencor, Inc. | Optimized anti-CD20 monoclonal antibodies having Fc variants |
| DOP2006000029A (es) | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
| US10155816B2 (en) | 2005-11-28 | 2018-12-18 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
| UA107557C2 (xx) * | 2007-07-06 | 2015-01-26 | Композиція антитіла офатумумабу | |
| TW201438738A (zh) | 2008-09-16 | 2014-10-16 | Genentech Inc | 治療進展型多發性硬化症之方法 |
| EP2600861A1 (en) | 2010-08-02 | 2013-06-12 | Sanofi-Aventis U.S. LLC | Use of teriflunomide for treating multiple sclerosis |
| JP2014506258A (ja) * | 2011-01-10 | 2014-03-13 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | 新規使用 |
| MX363819B (es) * | 2012-02-08 | 2019-04-03 | Igm Biosciences Inc | Uniones a cdim y sus usos. |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| EP2882741B1 (en) * | 2012-08-10 | 2018-10-24 | Boehringer Ingelheim International GmbH | Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors |
| WO2015162504A1 (en) | 2014-04-23 | 2015-10-29 | Novartis Ag | Novel dosing and uses of ofatumumab |
| UY36099A (es) | 2014-04-29 | 2016-02-29 | Teva Pharma | Laquinimod para el tratamiento de pacientes con esclerosis múltiple remitente recurrente (rrms) con un alto grado de discapacidad |
| EP3250927B1 (en) | 2015-01-28 | 2020-02-19 | H. Hoffnabb-La Roche Ag | Gene expression markers and treatment of multiple sclerosis |
| CN106699886A (zh) | 2015-07-13 | 2017-05-24 | 西藏海思科药业集团股份有限公司 | 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体 |
| CN109641965A (zh) | 2016-08-15 | 2019-04-16 | 诺华股份有限公司 | 使用奥法木单抗治疗多发性硬化的方案和方法 |
| CN118403156A (zh) | 2019-09-11 | 2024-07-30 | 诺华股份有限公司 | 通过转换疗法治疗rms |
| US20220389109A1 (en) | 2019-09-11 | 2022-12-08 | Novartis Ag | Management of conditions other than multiple sclerosis in ofatumumab-treated patients |
| IL296701A (en) | 2020-04-09 | 2022-11-01 | Novartis Ag | Ofatumumab for the treatment of multiple sclerosis while maintaining IgG in the serum |
| WO2022219057A1 (en) | 2021-04-14 | 2022-10-20 | Novartis Ag | Ofatumumab for treating multiple sclerosis in asian patients |
| US20240343821A1 (en) | 2021-08-16 | 2024-10-17 | Novartis Ag | Ofatumumab for treating pediatric ms |
-
2017
- 2017-08-11 CN CN201780049932.7A patent/CN109641965A/zh active Pending
- 2017-08-11 PL PL17768863T patent/PL3497132T3/pl unknown
- 2017-08-11 IL IL276890A patent/IL276890B2/en unknown
- 2017-08-11 RS RS20201066A patent/RS60807B1/sr unknown
- 2017-08-11 MX MX2019001860A patent/MX388593B/es unknown
- 2017-08-11 FI FIEP20180938.1T patent/FI3733712T3/fi active
- 2017-08-11 DE DE202017007542.3U patent/DE202017007542U1/de active Active
- 2017-08-11 CN CN202510270924.1A patent/CN120000782A/zh active Pending
- 2017-08-11 US US16/324,619 patent/US11161909B2/en active Active
- 2017-08-11 EP EP24166956.3A patent/EP4371611A3/en active Pending
- 2017-08-11 PL PL20180938.1T patent/PL3733712T3/pl unknown
- 2017-08-11 CN CN202510270961.2A patent/CN120053639A/zh active Pending
- 2017-08-11 CN CN202510270941.5A patent/CN120053638A/zh active Pending
- 2017-08-11 KR KR1020207034140A patent/KR20200136503A/ko not_active Ceased
- 2017-08-11 IL IL302488A patent/IL302488B2/en unknown
- 2017-08-11 EP EP17768863.7A patent/EP3497132B1/en active Active
- 2017-08-11 ES ES20180938T patent/ES2954259T3/es active Active
- 2017-08-11 EP EP20180938.1A patent/EP3733712B1/en active Active
- 2017-08-11 ES ES17768863T patent/ES2821924T3/es active Active
- 2017-08-11 RS RS20230635A patent/RS64541B1/sr unknown
- 2017-08-11 DK DK17768863.7T patent/DK3497132T3/da active
- 2017-08-11 KR KR1020197007454A patent/KR20190038914A/ko not_active Ceased
- 2017-08-11 SI SI201731396T patent/SI3733712T1/sl unknown
- 2017-08-11 LT LTEP20180938.1T patent/LT3733712T/lt unknown
- 2017-08-11 PT PT201809381T patent/PT3733712T/pt unknown
- 2017-08-11 LT LTEP17768863.7T patent/LT3497132T/lt unknown
- 2017-08-11 HR HRP20201388TT patent/HRP20201388T1/hr unknown
- 2017-08-11 IL IL313932A patent/IL313932A/en unknown
- 2017-08-11 SI SI201730400T patent/SI3497132T1/sl unknown
- 2017-08-11 PT PT177688637T patent/PT3497132T/pt unknown
- 2017-08-11 HR HRP20230894TT patent/HRP20230894T1/hr unknown
- 2017-08-11 JP JP2018550539A patent/JP6851391B2/ja active Active
- 2017-08-11 DK DK20180938.1T patent/DK3733712T3/da active
- 2017-08-11 AU AU2017311664A patent/AU2017311664C1/en active Active
- 2017-08-11 RU RU2019107146A patent/RU2749951C2/ru active
- 2017-08-11 HU HUE20180938A patent/HUE063625T2/hu unknown
- 2017-08-11 CN CN202510270903.XA patent/CN120037367A/zh active Pending
- 2017-08-11 CA CA3030530A patent/CA3030530C/en active Active
- 2017-08-11 CA CA3101514A patent/CA3101514A1/en active Pending
- 2017-08-11 EP EP23172507.8A patent/EP4252847A3/en active Pending
- 2017-08-11 HU HUE17768863A patent/HUE051948T2/hu unknown
- 2017-08-11 WO PCT/IB2017/054909 patent/WO2018033841A1/en not_active Ceased
- 2017-08-15 TW TW106127565A patent/TWI752995B/zh active
-
2019
- 2019-02-12 IL IL264804A patent/IL264804B/en active IP Right Grant
-
2020
- 2020-02-07 JP JP2020019337A patent/JP7198786B2/ja active Active
- 2020-02-17 AU AU2020201112A patent/AU2020201112C1/en active Active
- 2020-09-11 CY CY20201100861T patent/CY1123350T1/el unknown
-
2021
- 2021-10-06 US US17/495,559 patent/US20220081488A1/en not_active Abandoned
-
2023
- 2023-06-08 US US18/331,701 patent/US20240150485A1/en active Pending
-
2024
- 2024-03-06 US US18/597,624 patent/US12338290B2/en active Active
-
2025
- 2025-05-28 US US19/221,422 patent/US20250289902A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020100630A5 (enExample) | ||
| ES2762250T5 (es) | Tratamiento combinado del cáncer | |
| AU2013402794B2 (en) | Cancer treatment with combination of plinabulin and taxane | |
| JP2015187125A5 (enExample) | ||
| HRP20170056T2 (hr) | Terapija male učestalosti glatiramer acetatom | |
| JP2017132791A (ja) | 組み合わせ組成物 | |
| JP2020524129A (ja) | 再発膠芽腫（ｒｇｂｍ）の治療方法 | |
| CN110267648A (zh) | 毒蜥外泌肽(9-39)的缓冲制剂 | |
| JP2020500864A5 (enExample) | ||
| JP2024056908A (ja) | デュラグルチドを使用する方法およびデュラグルチドを含有する組成物 | |
| JP2019511506A5 (enExample) | ||
| JP2005525409A (ja) | タキサンにより惹起される神経毒性を予防又は軽減するための薬剤 | |
| US20240033328A1 (en) | Acth in the treatment of an adrenocorticotropic hormone responsive pediatric disorder | |
| JP2005529152A5 (enExample) | ||
| Chaplin et al. | Plegridy for the treatment of RRMS in adults | |
| US20250304696A1 (en) | Methods and compositions for treating barth syndrome | |
| KR20120089444A (ko) | 정맥내 이부프로펜에 의한 위독한 환자의 치료방법 | |
| JP2025084047A (ja) | 神経内分泌腫瘍又はソマトスタチン受容体を高発現する他の腫瘍に対するルテチウム－１７７ｄｏｔａｔｏｃペプチド受容体放射性核種療法の投与のための安全で効果的なプラットフォームの開発 | |
| WO2019211829A1 (en) | Compositions and methods for treating glioblastoma | |
| JPWO2019186369A5 (enExample) | ||
| WO2020160813A1 (en) | Method of treatment and pharmaceutical dosage form | |
| WO2025078463A1 (en) | Extended dosing regimens for anti-cd20 antibodies in the treatment of multiple sclerosis | |
| TW201728338A (zh) | 免疫球蛋白ｇ組合物 | |
| RU2025114624A (ru) | Способы модуляции экспрессии фактора комплемента b | |
| US20070167528A1 (en) | Methods of treating hepatocellular carcinoma with denspm |